Stocktoria
Edwards Lifesciences Corp EW
Edwards Lifesciences Corp (EW) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $6.1B at a 17.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.61 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-07-25 | Leerink Partners | Outperform (up) |
| 2026-07-24 | JP Morgan | Overweight (main) |
| 2026-07-24 | Piper Sandler | Overweight (reit) |
| 2026-07-16 | Truist Securities | Hold (main) |
| 2026-07-15 | Mizuho | Outperform (main) |
| 2026-07-13 | RBC Capital | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.36 |
| Retained earnings / assets | 1.04 |
| EBIT / assets | 0.092 |
| Equity / liabilities | 3.077 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| EW | Edwards Lifesciences Corp | 6/9 | 9.6 | 48.7 | +11.5% |
| STE | STERIS plc | 9/9 | 4.5 | 26.9 | +8.7% |
| ALGN | ALIGN TECHNOLOGY INC | 6/9 | 4.56 | 31.1 | +0.9% |
| ZBH | ZIMMER BIOMET HOLDINGS, INC. | 5/9 | 3.96 | 24.5 | +7.2% |
| ENOV | Enovis CORP | 4/9 | -1.51 | — | +6.7% |
| ISRG | INTUITIVE SURGICAL INC | 6/9 | 12.06 | 50.2 | +20.5% |
| MSA | MSA Safety Inc | 6/9 | 5.65 | 23.6 | +3.7% |
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
FAQ
Is EW financially healthy?
Edwards Lifesciences Corp's Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does EW pay a dividend?
No, Edwards Lifesciences Corp does not currently pay a dividend.
How profitable is EW?
In FY2025, Edwards Lifesciences Corp had a net margin of 17.7% and a return on equity of 10.4%.
Is EW overvalued or undervalued?
Edwards Lifesciences Corp trades at about 50.8× trailing earnings — above its 10-year norm (10-year range 10.4×–63.5×, median 44.7×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for EW?
The average Wall-Street price target for Edwards Lifesciences Corp is $100.96, about 8.5% above the recent price, from 26 analysts (consensus: buy).
Is EW a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Edwards Lifesciences Corp: a Piotroski F-score of 6/9, an Altman Z″ in the safe zone, a P/E of about 48.7×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.